Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

PURPOSE: The Study of Tamoxifen and Raloxifene (STAR) demonstrated that raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer (IBC) in postmenopausal women and had lower risks of thromboembolic events, endometrial cancer, and cataracts but had a nonstatistically sig...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Freedman, Andrew N., Yu, Binbing, Gail, Mitchell H., Costantino, Joseph P., Graubard, Barry I., Vogel, Victor G., Anderson, Garnet L., McCaskill-Stevens, Worta
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2011
Soggetti:
Original Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107748/
https://ncbi.nlm.nih.gov/pubmed/21537036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.33.0258
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi